Pacific Edge Appoints Chief Operating Officer

Thu, Jul 28 2022 09:12 am

Pacific Edge Appoints Chief Operating Officer

Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) is today pleased to announce the appointment of Darrell Morgan as Chief Operating Officer.

Darrell has extensive experience in senior leadership and executive roles in large, mid-sized and virtual pharmaceutical companies in the UK, Europe and New Zealand. He has more than 37 years’ experience in pharmaceutical R&D, immunodiagnostics and device development for drug delivery across human and animal health, in R&D, technical operations and customer-facing roles.

As Chief Operating Officer, Darrell will be a key leader in the Dunedin office, and responsible for Pacific Edge’s global laboratory operations, manufacturing, logistics, inventory management, the quality and regulatory compliance functions and operationalizing people and culture initiatives. He will have a focus on project management, people and culture, and operational excellence to optimize effectiveness, efficiency and on time delivery of products and services.

Darrell will join Pacific Edge on 3 October 2022 and report to Chief Executive Dr Peter Meintjes as a member of the C-Suite team. He will be based in Dunedin.

Since 2013, Darrell has been a senior leader with animal health company Argenta Research where his roles have included Global Head of Pharmaceutical Sciences, VP Customer Relationships – Pharmaceutical Sciences, and Product Development Director – Technical Operations. Prior to Argenta Research, he worked for global biopharmaceutical company UCB in the UK for eight years in senior roles with a focus on sterile drug product and medical device development.

Pacific Edge Chief Executive Dr Peter Meintjes, said: “We are delighted to welcome Darrell to Pacific Edge. His experience in global organizations of varied sizes in a range of roles focused on product and service delivery will be of great value to Pacific Edge and its partners and customers as we continue to drive increased adoption of our suite of Cxbladder diagnostics.”

Darrell said: “I have been impressed by the strong momentum I have seen from Pacific Edge as it expands globally, with a focus on the US. I look forward to working with the team to ensure quality and scale continues as the company grows.”

Darrell is a chartered biologist, with post graduate diplomas in industrial pharmaceutical sciences and management, people and change.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.  

For more information:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

Richard Inder
The Project
P: +64 21 645 643

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.

Announcement PDF

Markets News

NZ sharemarket down 1.13% for the week
Markets Market close

NZ sharemarket down 1.13% for the week

The S&P/NZX 50 Index closed at 11,796.21, down 39.83 points or 0.34%.

Graham Skellern 19 Apr 2024
Primary Sector

Bell Potter boosts Santana target price 53.5%

Aussie brokers increasingly like the look of a low-cost, high yield Otago gold play.

Pattrick Smellie 19 Apr 2024
Bell Potter boosts Santana target price 53.5%

Analysts upbeat about Tower's latest guidance

The insurer's shares have gained 36% so far this year. 

Rebecca Howard 19 Apr 2024
Analysts upbeat about Tower's latest guidance